PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
Abstract Background Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death worldwide. Although immune checkpoint inhibitors (ICIs) have shown remarkable clinical efficacy, they can also induce a paradoxical cancer acceleration, known as hyperprogressive disease (HPD), whose causativ...
| Published in: | Journal of Translational Medicine |
|---|---|
| Main Authors: | Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-024-06023-8 |
Similar Items
Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01)
by: Xue‐jiao Han, et al.
Published: (2020-09-01)
Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)
by: R. Riera-Sala, et al.
Published: (2023-09-01)
Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020-12-01)
by: Marta Brambilla, et al.
Published: (2020-12-01)
Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01)
by: Jan Skacel, et al.
Published: (2023-12-01)
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
by: Zhanqi Wei, et al.
Published: (2022-05-01)
by: Zhanqi Wei, et al.
Published: (2022-05-01)
Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer
by: Jie Zhou, et al.
Published: (2025-04-01)
by: Jie Zhou, et al.
Published: (2025-04-01)
Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
by: Kosuke Masuda, et al.
Published: (2023-11-01)
by: Kosuke Masuda, et al.
Published: (2023-11-01)
Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
by: Yong Jun Choi, et al.
Published: (2020-10-01)
by: Yong Jun Choi, et al.
Published: (2020-10-01)
Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
by: Alkader Mohammad S., et al.
Published: (2024-03-01)
by: Alkader Mohammad S., et al.
Published: (2024-03-01)
Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review
by: Kang-Xin Wang, et al.
Published: (2025-03-01)
by: Kang-Xin Wang, et al.
Published: (2025-03-01)
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
by: Romain Varnier, et al.
Published: (2021-09-01)
by: Romain Varnier, et al.
Published: (2021-09-01)
Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
by: Caner Acar, et al.
Published: (2024-10-01)
by: Caner Acar, et al.
Published: (2024-10-01)
Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023-08-01)
by: Shiyun Chen, et al.
Published: (2023-08-01)
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
by: Yikun Li, et al.
Published: (2024-12-01)
by: Yikun Li, et al.
Published: (2024-12-01)
Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis
by: Bo Pei, et al.
Published: (2024-09-01)
by: Bo Pei, et al.
Published: (2024-09-01)
First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review
by: Ya-Zhou Wang, et al.
Published: (2024-10-01)
by: Ya-Zhou Wang, et al.
Published: (2024-10-01)
Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
by: Daniela R. Montagna, et al.
Published: (2022-08-01)
by: Daniela R. Montagna, et al.
Published: (2022-08-01)
Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease
by: Daria Kravchuk, et al.
Published: (2025-02-01)
by: Daria Kravchuk, et al.
Published: (2025-02-01)
Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
by: Yan Chen, et al.
Published: (2020-07-01)
by: Yan Chen, et al.
Published: (2020-07-01)
Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion
by: Yiyue Huang, et al.
Published: (2024-11-01)
by: Yiyue Huang, et al.
Published: (2024-11-01)
Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
by: Yaping Long, et al.
Published: (2023-09-01)
by: Yaping Long, et al.
Published: (2023-09-01)
Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
by: Zijun Zhao, et al.
Published: (2022-08-01)
by: Zijun Zhao, et al.
Published: (2022-08-01)
Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report
by: Yao Zhang, et al.
Published: (2024-12-01)
by: Yao Zhang, et al.
Published: (2024-12-01)
Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)
by: Wang X, et al.
Published: (2023-01-01)
Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
by: Yanping Li, et al.
Published: (2023-05-01)
by: Yanping Li, et al.
Published: (2023-05-01)
Incidence of immunotherapy‐related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta‐analysis
by: Min Jeong Kim, et al.
Published: (2024-02-01)
by: Min Jeong Kim, et al.
Published: (2024-02-01)
Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
by: Rui Zhou, et al.
Published: (2023-11-01)
by: Rui Zhou, et al.
Published: (2023-11-01)
Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature
by: Guangjian Yang, et al.
Published: (2025-01-01)
by: Guangjian Yang, et al.
Published: (2025-01-01)
Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
by: Yada Kanjanapan MBBS, et al.
Published: (2023-10-01)
by: Yada Kanjanapan MBBS, et al.
Published: (2023-10-01)
Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review
by: Jiajie He, et al.
Published: (2023-11-01)
by: Jiajie He, et al.
Published: (2023-11-01)
Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
by: Huijie Zhou, et al.
Published: (2023-03-01)
by: Huijie Zhou, et al.
Published: (2023-03-01)
Advances of the Correlation between Driver Gene Status and Immunotherapy
in Non-small Cell Lung Cancer
by: Jie CHEN, et al.
Published: (2019-04-01)
by: Jie CHEN, et al.
Published: (2019-04-01)
Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
by: Francesca Giunchi, et al.
Published: (2020-12-01)
by: Francesca Giunchi, et al.
Published: (2020-12-01)
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
by: Francesca Ruzzi, et al.
Published: (2024-10-01)
by: Francesca Ruzzi, et al.
Published: (2024-10-01)
A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice
by: Guo Hanfei, et al.
Published: (2021-12-01)
by: Guo Hanfei, et al.
Published: (2021-12-01)
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients
by: Francesca Romana Di Pietro, et al.
Published: (2024-08-01)
by: Francesca Romana Di Pietro, et al.
Published: (2024-08-01)
New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Andrea Alberti, et al.
Published: (2022-06-01)
by: Andrea Alberti, et al.
Published: (2022-06-01)
Case report: Molecular characterization of adult atypical teratoid rhabdoid tumor and review of the literature
by: Miguel A. Hernandez-Rovira, et al.
Published: (2025-02-01)
by: Miguel A. Hernandez-Rovira, et al.
Published: (2025-02-01)
Advanced Merkel cell carcinoma in setting of pembrolizumab therapy for squamous cell carcinoma
by: Henry Jeon, BSc, et al.
Published: (2024-05-01)
by: Henry Jeon, BSc, et al.
Published: (2024-05-01)
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)
by: Laura Scalambra, et al.
Published: (2025-01-01)
Similar Items
-
Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01) -
Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01) -
Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020-12-01) -
Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01) -
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
by: Zhanqi Wei, et al.
Published: (2022-05-01)
